Static tool
Mechanism map
Static map of the major receptor pathways relevant to metabolic peptide research: GLP-1, GIP, glucagon, GHRH, GHS-R1a, amylin, PYY, oxyntomodulin and lipolytic fragments. Each pathway links to molecules, trials and safety pages.
GLP-1 receptor
/mechanisms/glp-1-receptor-signalling
Safety signals
What this pathway does not prove: GLP-1 receptor agonism does not guarantee CV / renal / hepatic outcome benefit for every agent or population.
GIP receptor
/mechanisms/gip-receptor-signalling
Safety signals
What this pathway does not prove: GIP receptor activity is not a simple add-on to GLP-1; the integrated pharmacology of dual agonism is complex.
Glucagon receptor
/mechanisms/glucagon-receptor-agonism
Trials
Safety signals
— no items linked yet
What this pathway does not prove: Glucagon-receptor agonism in obesity / metabolic combinations remains investigational; long-term outcome and safety data are pending.
GHRH receptor
/mechanisms/gh-axis-visceral-adiposity
What this pathway does not prove: Tesamorelin's licensed indication is HIV-associated lipodystrophy, not generic obesity.
GHS-R1a / ghrelin receptor
/mechanisms/ghrh-vs-ghrelin-mimetic-secretagogues
Trials
— no items linked yet
Safety signals
— no items linked yet
What this pathway does not prove: Research-only growth-hormone secretagogues do not have human-use evidence comparable to incretin medicines.
Amylin / amylin combinations
/mechanisms
Trials
— no items linked yet
Safety signals
— no items linked yet
What this pathway does not prove: Amylin combinations are investigational; phase 3 confirmation of weight, glycaemic and outcome benefit is pending.
Lipolytic fragments
/mechanisms/lipolysis-vs-lipogenesis
What this pathway does not prove: Lipolytic peptide fragments have preclinical-heavy evidence and no licensed human therapeutic indication.
- It does not establish that activating any one receptor pathway will produce a desired clinical outcome.
- It does not provide dosing or self-experimentation guidance.
- It does not rank molecules by clinical superiority.